कंपनी का अवलोकन
TELA Bio, Inc. operates as a commercial-stage medical technology entity dedicated to delivering soft-tissue reconstruction solutions that enhance clinical outcomes through the prioritization of anatomical preservation and restoration. The company functions within the Healthcare sector, specifically targeting the Medical Devices industry, which implies a focus on tangible products utilized in clinical settings rather than pure service-based healthcare models. At present, the organization reports a market capitalization of $28.47M and generates annual revenue of $80.28M, while the specific employee count is listed as N/A in available records. These valuation and revenue figures indicate that TELA Bio, Inc. occupies a niche position in the medical device landscape, characterized by a relatively small market cap that suggests limited scale compared to large-cap pharmaceutical or technology peers, yet supported by a robust revenue stream relative to its valuation.
वित्तीय स्वास्थ्य
The company reported a Total Revenue of $80.28M over the trailing twelve months, alongside a Net Income of -$38,831,000 and an EBITDA of -$32,745,000, revealing a significant gap where operating expenses substantially exceed gross profit generation. This substantial disparity between revenue and net income highlights a cost structure burdened by high operational costs, likely driven by research and development expenditures or general administrative overhead common in early-to-mid-stage commercial medical technology firms. Free Cash Flow stands at -$16,954,000, indicating that the company is currently consuming cash rather than generating surplus liquidity, which limits immediate financial flexibility for discretionary spending or shareholder returns without external capital injection. Margin analysis reveals a Gross Margin of 68.2%, suggesting efficient production and pricing power on the core product portfolio, contrasted sharply by an Operating Margin of -31.9% and a Profit Margin of -48.4%, which underscores the high fixed costs associated with bringing new medical technologies to market before achieving profitability. The balance sheet shows a Cash position of $50.84M against Total Debt of $57.65M, resulting in a Debt to Equity ratio of 913.26, which characterizes the entity as highly leveraged and reliant on equity financing rather than debt capacity. Despite the high leverage, the Current Ratio is reported at 4.21, indicating a strong ability to meet short-term obligations with its liquid assets, providing a buffer against immediate liquidity crises. Return on Equity is calculated at -223.4% and Return on Assets at -25.1%, metrics that reflect management's current inability to generate positive returns on the capital invested in the business, a typical characteristic for growth-stage firms prioritizing expansion over immediate profitability.
मूल्यांकन आकलन
The Trailing Twelve Months P/E Ratio is N/A due to negative earnings, while the Forward P/E is listed as -1.13, a metric that is technically undefined in traditional analysis but here reflects the negative earnings expectation embedded in the forward consensus. The Price to Book ratio stands at 4.48, indicating that the market values the company at a significant premium over its tangible book value, suggesting investor confidence in the intangible value of its medical device portfolio despite current losses. The Price to Sales ratio is 0.35, and the EV/EBITDA is -1.08, alternative metrics that suggest the company is being valued based on revenue multiples rather than earnings power, a common practice for pre-profitability healthcare technology companies. The stock has traded within a 52-week range with a high of $2.20 and a low of $0.50, and given the market capitalization and recent trading activity, the current price sits within this volatility band, reflecting the high uncertainty associated with its commercialization phase. The Beta is 0.99, which indicates that the stock's price volatility moves in tandem with the broader market, lacking the typical high-beta amplification seen in speculative small-cap biotech stocks but still subject to significant market-wide fluctuations.
Growth & Income
Revenue Growth Year over Year is recorded at 18.2%, while Earnings Growth is N/A due to the lack of positive earnings, implying that the company is still in a cash-burning phase where top-line expansion is the primary driver of value creation rather than bottom-line improvement. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that all available cash flow is retained within the business to fund operations and growth initiatives rather than being distributed to shareholders. This reinvestment strategy is consistent with the company's stage of development, where capital is directed toward scaling the OviTex Reinforced Tissue Matrix portfolio and optimizing clinical outcomes rather than providing current income to investors. The overall growth and income profile presents a classic high-risk, high-reward scenario typical of medical device firms that have achieved product approval but have not yet reached the break-even threshold required to sustain dividends or positive earnings growth.